Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Living Guideline, Version 2026.1.2

Shah M.A.; Marzalik J.S.; Kennedy E.B.; Deighton D.; Hamedi Z.; Jhawer M.; Kadakia K.C.; Montenegro P.; Mukherjee S.; Nevala-Plagemann C.; Saeed A.; Schneider B.J.; Semrad T.; Shitara K.; Vincelli M.; Rajdev L. · Journal of Clinical Oncology (2026) · DOI: 10.1200/jco-26-01944

Resumen

This guideline has been updated.This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the online dynamic version for the latest updates. Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information (Appendix I and Appendix II). Updates are published regularly and can be found on the ASCO Publications website.